High-Throughput Analysis of an RNAi Library Identifies Novel Kinase Targets in Trypanosoma brucei

Chemical Biology and Drug Design

Volumn 78, Issue 3, 2011, Pages 454-463

  Mackey, Zachary B ^a   Koupparis, Kyriacos ^a   Nishino, Mari ^a   Mckerrow, James H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenosine triphosphate bioluminescence; High throughput screening; RNA interference; Target; Trypanosoma brucei

Indexed keywords

CDC2 RELATED KINASE 12; EXTRACELLULAR SIGNAL REGULATED KINASE 8; LUCIFERASE; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG TARGETING; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TRYPANOSOMA BRUCEI;

ANIMALS; DRUG DISCOVERY; HUMANS; PHOSPHOTRANSFERASES; RNA INTERFERENCE; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

TRYPANOSOMA BRUCEI;

EID: 80051590688     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01156.x     Document Type: Article

References (35)

1. Sassi F. (2006) Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan;21:402-408.
2. King C.H., Bertino A.M. (2008) Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Negl Trop Dis;2:e209.
3. Blum J., Burri C. (2002) Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. Swiss Med Wkly;132:51-56.
4. Burchmore R.J., Ogbunude P.O., Enanga B., Barrett M.P. (2002) Chemotherapy of human African trypanosomiasis. Curr Pharm Des;8:256-267.
5. Nok A.J. (2003) Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res;90:71-79.
6. Kennedy P.G. (2004) Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest;113:496-504.
7. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., Lydon N.B. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res;56:100-104.
8. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med;2:561-566.
9. O'Dwyer M.E., Druker B.J. (2000) STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol;1:207-211.
10. Capdeville R., Buchdunger E., Zimmermann J., Matter A. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov;1:493-502.
11. Wang Z., Morris J.C., Drew M.E., Englund P.T. (2000) Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J Biol Chem;275:40174-40179.
12. Mackey Z.B., Baca A.M., Mallari J.P., Apsel B., Shelat A., Hansell E.J., Chiang P.K., Wolff B., Guy K.R., Williams J., McKerrow J.H. (2006) Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des;67:355-363.
13. Sui Y., Wu Z. (2007) Alternative statistical parameter for high-throughput screening assay quality assessment. J Biomol Screen;12:229-234.
14. Zhang J.H., Chung T.D., Oldenburg K.R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen;4:67-73.
15. Berriman M., Ghedin E., Hertz-Fowler C., Blandin G., Renauld H., Bartholomeu D.C., Lennard N.J. et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science;309:416-422.
16. El-Sayed N.M., Myler P.J., Blandin G., Berriman M., Crabtree J., Aggarwal G., Caler E., Renauld H., Worthey E.A., Hertz-Fowler C. (2005) Comparative genomics of trypanosomatid parasitic protozoa. Science;309:404-409.
17. Parsons M., Worthey E.A., Ward P.N., Mottram J.C. (2005) Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics;6:127.
18. Nett I.R., Martin D.M., Miranda-Saavedra D., Lamont D., Barber J.D., Mehlert A., Ferguson M.A. (2009) The phosphoproteome of bloodstream form Trypanosoma brucei, causative agent of African sleeping sickness. Mol Cell Proteomics;8:1527-1538.
19. Tu X., Wang C.C. (2005) Pairwise knockdowns of cdc2-related kinases (CRKs) in Trypanosoma brucei identified the CRKs for G1/S and G2/M transitions and demonstrated distinctive cytokinetic regulations between two developmental stages of the organism. Eukaryot Cell;4:755-764.
20. Raz B., Iten M., Grether-Buhler Y., Kaminsky R., Brun R. (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop;68:139-147.
21. Ahmed S.A., Gogal R.M. Jr, Walsh J.E. (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods;170:211-224.
22. Subramaniam C., Veazey P., Redmond S., Hayes-Sinclair J., Chambers E., Carrington M., Gull K., Matthews K., Horn D., Field M.C. (2006) Chromosome-wide analysis of gene function by RNA interference in the african trypanosome. Eukaryot Cell;5:1539-1549.
23. Burkard G., Fragoso C.M., Roditi I. (2007) Highly efficient stable transformation of bloodstream forms of Trypanosoma brucei. Mol Biochem Parasitol;153:220-223.
24. Schumann Burkard G., Jutzi P., Roditi I. (2011) Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. Mol Biochem Parasitol;175:91-94.
25. Wirtz E., Hoek M., Cross G.A. (1998) Regulated processive transcription of chromatin by T7 RNA polymerase in Trypanosoma brucei. Nucleic Acids Res;26:4626-4634.
26. Alibu V.P., Storm L., Haile S., Clayton C., Horn D. (2005) A doubly inducible system for RNA interference and rapid RNAi plasmid construction in Trypanosoma brucei. Mol Biochem Parasitol;139:75-82.
27. Alsford S., Kawahara T., Glover L., Horn D. (2005) Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. Mol Biochem Parasitol;144:142-148.
28. Abe M.K., Saelzler M.P., Espinosa R. III, Kahle K.T., Hershenson M.B., Le Beau M.M., Rosner M.R. (2002) ERK8, a new member of the mitogen-activated protein kinase family. J Biol Chem;277:16733-16743.
29. Klevernic I.V., Martin N.M., Cohen P. (2009) Regulation of the activity and expression of ERK8 by DNA damage. FEBS Lett;583:680-684.
30. Erster O., Seger R., Liscovitch M. (2010) Ligand interaction scan (LIScan) in the study of ERK8. Biochem Biophys Res Commun;399:37-41.
31. Groehler A.L., Lannigan D.A. (2010) A chromatin-bound kinase, ERK8, protects genomic integrity by inhibiting HDM2-mediated degradation of the DNA clamp PCNA. J Cell Biol;190:575-586.
32. Li Y., Li Z., Wang C.C. (2003) Differentiation of Trypanosoma brucei may be stage non-specific and does not require progression of cell cycle. Mol Microbiol;49:251-265.
33. Tu X., Wang C.C. (2004) The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-specific phenotypes caused by CRK3 depletion. J Biol Chem;279:20519-20528.
34. Van Hellemond J.J., Neuville P., Schwarz R.T., Matthews K.R., Mottram J.C. (2000) Isolation of Trypanosoma brucei CYC2 and CYC3 cyclin genes by rescue of a yeast G(1) cyclin mutant. Functional characterization of CYC2. J Biol Chem;275:8315-8323.
35. Hammarton T.C., Clark J., Douglas F., Boshart M., Mottram J.C. (2003) Stage-specific differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin. J Biol Chem;278:22877-22886.